| Familial hypercholesterolemia - heterozygous
Leqvio vs Repatha
Side-by-side clinical, coverage, and cost comparison for familial hypercholesterolemia - heterozygous.Deep comparison between: Leqvio vs Repatha with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRepatha has a higher rate of injection site reactions vs Leqvio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Repatha but not Leqvio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Leqvio
Repatha
At A Glance
SC injection
Every 6 months (after initial doses)
PCSK9 siRNA
SC injection
Every 2 weeks or monthly
PCSK9 inhibitor
Indications
- Hypercholesterolemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
- Hypercholesterolemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
Dosing
Hypercholesterolemia, Familial hypercholesterolemia - heterozygous, Homozygous Familial Hypercholesterolemia 284 mg SC injection initially, again at 3 months, then every 6 months; administered by a healthcare professional into abdomen, upper arm, or thigh.
Hypercholesterolemia, Familial hypercholesterolemia - heterozygous 140 mg every 2 weeks or 420 mg once monthly administered subcutaneously.
Homozygous Familial Hypercholesterolemia 420 mg once monthly subcutaneously; may increase to 420 mg every 2 weeks if a clinically meaningful response is not achieved in 12 weeks.
Contraindications
- Prior serious hypersensitivity reaction to inclisiran or any excipient in LEQVIO (including anaphylaxis and angioedema)
- History of serious hypersensitivity reaction to evolocumab or any excipient in REPATHA
Adverse Reactions
Most common (>=3%) Injection site reaction, arthralgia, bronchitis
Postmarketing Anaphylaxis, angioedema, rash, pruritus, urticaria
Most common (>=3%) Nasopharyngitis, upper respiratory tract infection, influenza, back pain, injection site reactions, cough, urinary tract infection, sinusitis, headache, myalgia, dizziness, musculoskeletal pain, hypertension, diarrhea, gastroenteritis
Serious Hypersensitivity reactions including angioedema
Postmarketing Angioedema, influenza-like illness
Pharmacology
PCSK9 siRNA; inclisiran is a double-stranded siRNA conjugated with GalNAc that directs catalytic breakdown of PCSK9 mRNA in hepatocytes, increasing LDL-C receptor recycling and expression on the hepatocyte cell surface to reduce circulating LDL-C.
Evolocumab is a human monoclonal IgG2 antibody that inhibits PCSK9, thereby increasing LDL receptor availability on hepatocytes and lowering LDL-C levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Leqvio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Repatha
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (10/12) · Qty limit (11/12)
UnitedHealthcare
Leqvio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Repatha
- Covered on 4 commercial plans
- PA (3/8) · Step Therapy (3/8) · Qty limit (7/8)
Humana
Leqvio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Repatha
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Hypercholesterolemia - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAmgen Safety Net Foundation: Repatha
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LeqvioView full Leqvio profile
RepathaView full Repatha profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.